Ophthalmic compositions

Information

  • Patent Grant
  • 11590123
  • Patent Number
    11,590,123
  • Date Filed
    Wednesday, July 6, 2022
    2 years ago
  • Date Issued
    Tuesday, February 28, 2023
    a year ago
Abstract
The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.
Description
INTRODUCTION

Ophthalmic compositions are needed which provide sufficient solubility for the active pharmaceutical ingredient, while maintaining stability of the active pharmaceutical ingredient and reducing discomfort upon administration. Typically ophthalmic compositions are administered at or near physiological pH for both ease of dosing and reduced discomfort upon administration. However, not all active pharmaceutical ingredients are sufficiently soluble at physiological pH. Therefore, a composition that both allows for sufficient solubility of the active pharmaceutical ingredient and minimizes discomfort upon administration is needed.







DETAILED DESCRIPTION

In an aspect, the present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.


In another aspect, the present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; boric acid; and mannitol, wherein the composition has a pH from about 4.5 to about 5.2.


In another aspect, the present disclosure provides an ophthalmic composition comprising about 0.02% weight/volume of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salt; about 4.7% weight/volume of mannitol; about 0.05% weight/volume of boric acid; and about 0.015% weight/volume of benzalkonium chloride; wherein the composition has a pH from about 4.5 to about 5.2.


In another aspect, the present disclosure provides an ophthalmic composition, comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; boric acid; mannitol; and latanoprost.


In another aspect, the present disclosure provides methods of treating an ophthalmic disease, the method comprising topically administering to the eye of a patient in need an ophthalmic composition as described herein.


1. DEFINITIONS

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In case of conflict, the present document, including definitions, will control. Preferred methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in practice or testing of the present disclosure. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. The materials, methods, and examples disclosed herein are illustrative only and not intended to be limiting.


The terms “comprise(s),” “include(s),” “having,” “has,” “can,” “contain(s),” and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that do not preclude the possibility of additional acts or structures. The singular forms “a,” “an” and “the” include plural references unless the context clearly dictates otherwise. The present disclosure also contemplates other embodiments “comprising,” “consisting of” and “consisting essentially of,” the embodiments or elements presented herein, whether explicitly set forth or not.


The conjunctive term “or” includes any and all combinations of one or more listed elements associated by the conjunctive term. For example, the phrase “an apparatus comprising A or B” may refer to an apparatus including A where B is not present, an apparatus including B where A is not present, or an apparatus where both A and B are present. The phrases “at least one of A, B, . . . and N” or “at least one of A, B, . . . N, or combinations thereof” are defined in the broadest sense to mean one or more elements selected from the group comprising A, B, . . . and N, that is to say, any combination of one or more of the elements A, B, . . . or N including any one element alone or in combination with one or more of the other elements which may also include, in combination, additional elements not listed.


The modifier “about” used in connection with a quantity is inclusive of the stated value and has the meaning dictated by the context (for example, it includes at least the degree of error associated with the measurement of the particular quantity). The modifier “about” should also be considered as disclosing the range defined by the absolute values of the two endpoints. For example, the expression “from about 2 to about 4” also discloses the range “from 2 to 4.” The term “about” may refer to plus or minus 10% of the indicated number. For example, “about 10%” may indicate a range of 9% to 11%, and “about 1” may mean from 0.9-1.1. Other meanings of “about” may be apparent from the context, such as rounding off, so, for example “about 1” may also mean from 0.5 to 1.4.


For the recitation of numeric ranges herein, each intervening number there between with the same degree of precision is explicitly contemplated. For example, for the range of 6-9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the number 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are explicitly contemplated.


2. COMPOSITIONS

In an aspect, the present disclosure provides an ophthalmic composition comprising netarsudil or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.


a. 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate

In another aspect, provided herein are ophthalmic compositions, comprising: 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.


In another aspect, provided herein are ophthalmic compositions, comprising: (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof; boric acid; and mannitol; wherein the composition has a pH from about 4.5 to about 5.2.


In another aspect, provided herein are ophthalmic compositions, comprising: about 0.02% to about 0.03% weight/volume of (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof; about 4.7% weight/volume of mannitol; about 0.05% weight/volume of boric acid; and about 0.015% weight/volume of benzalkonium chloride; wherein the composition has a pH from about 4.5 to about 5.2.


In another aspect, provided herein are ophthalmic compositions, comprising: (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof; boric acid; mannitol; and latanoprost.


In another aspect, provided herein are ophthalmic compositions, comprising: mixture of (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof and (R)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof; boric acid; and mannitol; wherein the composition has a pH from about 4.5 to about 5.2.


In another aspect, provided herein are ophthalmic compositions, comprising: about 0.02% to about 0.03% weight/volume of a mixture of (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof and (R)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof; about 4.7% weight/volume of mannitol; about 0.05% weight/volume of boric acid; and about 0.015% weight/volume of benzalkonium chloride; wherein the composition has a pH from about 4.5 to about 5.2.


In another aspect, provided herein are ophthalmic compositions, comprising: a mixture of (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof and (R)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof; boric acid; mannitol; and latanoprost.


In some embodiments of the compositions provided herein, the pH is from about 3.5 to about 5.5.


In some embodiments of the compositions provided herein, the pH is from about 4.5 to about 5.2.


In some embodiments, the compositions further comprise a preservative.


In some embodiments, the preservative comprises benzalkonium chloride.


In some embodiments, the compositions further comprise an emulsifying agent.


In some embodiments, the emulsifying agent comprises polyoxyl 40 stearate, polyethoxylated castor oil, or a combination thereof.


In some embodiments, the tonicity agent comprises mannitol.


In some embodiments, the buffer comprises boric acid or its salts.


In some embodiments, the compositions further comprise water.


In some embodiments, the compositions further comprise a pH adjusting agent.


In some embodiments, the 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate is a dimesylate salt.


In some embodiments, the 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof is (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof.


In some embodiments, the compositions further comprise a second ophthalmic active compound.


In some embodiments, the second ophthalmic active compound is a prostaglandin analog.


In some embodiments, the prostaglandin analog is latanoprost or travoprost.


In some embodiments, the compositions comprise about 0.02% w/v to about 0.03% w/v of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof.


In some embodiments, the compositions comprise about 4.7% weight/volume of mannitol.


In some embodiments, the compositions comprise about 0.05% weight/volume of boric acid.


In some embodiments, the compositions comprise about 0.015% weight/volume of benzalkonium chloride.


In some embodiments, the compositions further comprise 0.005% weight/volume of latanoprost or travoprost.


In some embodiments, the pharmaceutically acceptable salt is the dimesylate salt.


In some embodiments, the pharmaceutically acceptable salt is the dihydrochloride salt.


In some embodiments, the pharmaceutically acceptable salt is the mesylate salt.


In some embodiments, the pharmaceutically acceptable salt is the hydrochloride salt.


4-(3-Amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts may be present in the ophthalmic composition in an amount of about 0.01% w/v to about 0.06% w/v. Suitably, 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts may be present in an amount of about 0.02% w/v to about 0.03% w/v, depending on the particular salt form. For example, 0.0285% w/v of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate dimesylate provides 0.02% w/v of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate free base; and 0.0233% w/v/of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate diHCI provides 0.02% w/v of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate free base. (S)-4-(3-Amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate dimesylate is also known as netarsudil mesylate.


In an embodiment, 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate may be an enantiomerically enriched isomer of a stereoisomer. For example, the 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate may have an enantiomeric excess of at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the (S)- or the (R)-enantiomer. Enantiomer, when used herein, refers to either of a pair of chemical compounds whose molecular structures have a mirror-image relationship to each other. In an embodiment, a preparation of a compound disclosed herein is enriched for an isomer of the compound having a selected stereochemistry, e.g., R or S, corresponding to a selected stereocenter. For example, the compound has a purity corresponding to a compound having a selected stereochemistry of a selected stereocenter of at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%.


The term “pharmaceutically acceptable salt” includes salts of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate that are prepared with relatively nontoxic acids. Neutral forms of the compounds may be regenerated by contacting the salt with a base and isolating the parent compound in a conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as molecular weight and solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of this disclosure. Examples of pharmaceutically acceptable salts are discussed in Berge et al, 1977, “Pharmaceutically Acceptable Salts.” J. Pharm. Sci. Vol. 66, pp. 1-19. In an embodiment, the compound is present in mono-salt form. In embodiments, the compound is present in di-salt form.


Examples of suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and phosphorous. Examples of suitable organic anions include, but are not limited to, those derived from the following organic acids: 2-acetyoxybenzoic, acetic, ascorbic, aspartic, benzoic, camphorsulfonic, cinnamic, citric, edetic, ethanedisulfonic, ethanesulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic, hydroxymaleic, hydroxynaphthalene carboxylic, isethionic, lactic, lactobionic, lauric, maleic, malic, ethanesulfonic acid, methanesulfonic, mucic, oleic, oxalic, palmitic, pamoic, pantothenic, phenylacetic, phenylsulfonic, propionic, pyruvic, salicylic, stearic, succinic, sulfanilic, tartaric, p-toluenesulfonic, and valeric. Examples of suitable polymeric organic anions include, but are not limited to, those derived from the following polymeric acids: tannic acid, carboxymethyl cellulose.


b. Buffers

The ophthalmic compositions may comprise a buffer. The buffer may serve to minimize pH drift of the composition and help to stabilize the composition. Suitable buffers include, but are not limited to, acetic acid, citric acid, carbonic acid, phosphoric acid, boric acid, the pharmaceutically acceptable salts thereof, tromethamine, and combinations thereof. The buffer may be present in the ophthalmic composition in an amount of from about 0.01% weight/volume to about 1% weight/volume or about 0.1% w/v to about 0.9% w/v, or about 0.3% w/v to about 0.8% w/v, or about 0.4% w/v to about 0.6% w/v. Suitably, the buffer may be present in at least 0.01% w/v, at least 0.05% w/v, at least 0.1% w/v, at least 0.3% w/v, or at least 0.5% w/v. Suitably, the buffer may be present in an amount of no more than 1.0% w/v, no more than 0.8% w/v, or no more than 0.6% w/v. In embodiments, the buffer may be present in the ophthalmic composition in an amount of about 0.03% w/v, about 0.04% w/v, about 0.05% w/v, about 0.06% w/v, or about 0.07% w/v. The buffer may suitably be boric acid.


c. Tonicity Agents

The tonicity, or osmolality, of the composition can be adjusted to hypotonicity, isotonicity, or hypertonicity relative to normal tears by use of conventional materials known in the art. Tonicity agents are typically nonionic compounds. Examples of tonicity agents include, but are not limited to, sodium chloride, potassium chloride, mannitol, dextrose, glycerine, and propylene glycol. Suitably, the tonicity agent may be present in the ophthalmic composition in an amount of from about 0.01% weight/volume to about 10% weight/volume or about 1% w/v to about 10% w/v, or about 2.5% w/v to about 7.5% w/v, or about 4% w/v to about 6% w/v. Suitably, the tonicity agent may be present in at least 0.01% w/v, at least 0.05% w/v, at least 1% w/v, at least 2.5% w/v, at least 4% w/v, or at least 5% w/v. Suitably, the tonicity agent may be present in an amount of no more than 10% w/v, no more than 7.5% w/v, no more than 6% w/v, or no more than 5% w/v. In embodiments, the tonicity agent may be present in the ophthalmic composition in an amount of about 4.5% w/v, about 4.6% w/v, about 4.7% w/v, about 4.8% w/v, or about 4.9 w/v %. The tonicity agent may suitably be mannitol.


d. Other Components

In embodiments, the composition may also contain pH adjusting agents in an amount sufficient to adjust the pH of the composition to between about 3.5 and about 5.5. Suitably, the ophthalmic composition may have a pH of about 4.5 to about 5.2 or about 4.5 to about 5.1. In some embodiments, the ophthalmic composition has a pH of about 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, or a range bounded by any two of these values. Suitable pH adjusting agents include, but are not limited to, sodium hydroxide.


In embodiments, the composition may also contain an emulsifying agent. Suitable emulsifying agents include, but are not limited to, polyoxyl 40 stearate, polyethoxylated castor oil, and combinations thereof, and other agents known to one skilled in the art. The emulsifying agent may be present in the ophthalmic composition in an amount of from about 0.01% weight/volume to about 1% weight/volume or about 0.1% w/v to about 0.9% w/v, or about 0.3% w/v to about 0.8% w/v, or about 0.4% w/v to about 0.6% w/v. Suitably, the emulsifying agent may be present in at least 0.01% w/v, at least 0.05% w/v, at least 0.1% w/v, at least 0.3% w/v, or at least 0.5% w/v. Suitably, the emulsifying agent may be present in an amount of no more than 1.0% w/v, no more than 0.8% w/v, or no more than 0.6% w/v. In embodiments, the emulsifying agent may be present in the ophthalmic composition in an amount of about 0.2% w/v, about 0.25% w/v, about 0.3% w/v, about 0.5% w/v, or about 0.75% w/v.


Ophthalmic compositions are typically packaged in unit dose or multidose form. Preservatives may be present to prevent or inhibit microbial contamination. Suitable preservatives include, but are not limited to, benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, boric acid, sorbic acid, or other agents known to one skilled in the art. If present, the preservative may be present in the ophthalmic composition in an amount of about 0.001% w/v to about 1.0% w/v, or about 0.01% w/v to about 1.0% w/v, or about 0.1% w/v to about 1.0% w/v. Suitably, the preservative may be present in at least 0.001% w/v, at least 0.005% w/v, at least 0.01% w/v, at least 0.05% w/v, at least 0.1% w/v, or at least 0.5% w/v. Suitably, the preservative may be present in an amount of no more than 1.0% w/v, no more than 0.9% w/v, no more than 0.5% w/v, or no more than 0.1% w/v. In some embodiments, the preservative may be present in the ophthalmic composition in an amount of about 0.005% w/v, about 0.010% w/v, about 0.015% w/v, about 0.020% w/v, about 0.025% w/v, or about 0.030% w/v. The preservative may suitably be benzalkonium chloride.


In embodiments, the composition may comprise a second active pharmaceutical ingredient. The second active pharmaceutical ingredient may be a prostaglandin, such as latanoprost or travoprost. If present, the second active pharmaceutical ingredient may be present in an amount of about 0.001% w/v to about 1.0% w/v, or about 0.01% w/v to about 1.0% w/v, or about 0.1% w/v to about 1.0% w/v. Suitably, the second active pharmaceutical ingredient may be present in at least 0.001% w/v, at least 0.005% w/v at least 0.01% w/v, at least 0.05% w/v, at least 0.1% w/v, or at least 0.5% w/v, at least 5% w/v. Suitably, the second active pharmaceutical ingredient may be present in an amount of no more than 1.0% w/v, no more than 0.9% w/v, no more than 0.5% w/v, or no more than 0.1% w/v.


Other components commonly used in ophthalmic compositions, such as surfactants, comfort-enhancing agents, solubilizing agents, antioxidants, and stabilizing agents, may also be present.


Typically, the buffer and tonicity agent are mixed with or without the preservative. 4-(3-Amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate dimesylate is then added to the mixture and stirred. Water is then added to bring the composition to 100%. The pH is then adjusted by adding pH adjusting agents.


3. FORMULATIONS AND METHODS OF USE

The ophthalmic formulations of the present disclosure may be formulated in various dosage forms suitable for topical ophthalmic delivery, including solutions, suspensions, emulsions, and gels. The compositions are suitably aqueous.


The present disclosure is also directed to methods of treating glaucoma and other ophthalmic diseases. As used herein, “treat” or “treating” as used herein refers to administering a regimen to the subject, e.g., the administration a compound or composition described herein, such that the disorder or at least one symptom of the disorder is healed, alleviated, relieved, altered, remedied, ameliorated, and/or improved. Treating includes administering an amount effective to alleviate, relieve, alter, remedy, ameliorate, improve and/or affect the disorder or the symptoms of the disorder. The treatment may inhibit deterioration or worsening of a symptom of a disorder.


The methods comprise topically applying to the affected eye(s) of the patient a therapeutically effective amount of a composition according to the present disclosure. The frequency and amount of dosage can be readily determined by one of skill in the art based on various clinical factors. The methods typically comprise topical application to the eye of one or two drops once or twice a day.


Thus, in one aspect, provided herein are methods of treating an ophthalmic disease in a subject in need thereof, the method comprising topically administering to an eye of a patient a composition provided herein. In some embodiments, the ophthalmic disease is glaucoma.


In some embodiments, provided herein are methods of treating glaucoma in a subject in need thereof, the method comprising topically administering to an eye of a patient an ophthalmic composition comprising: 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.


In some embodiments, provided herein are methods of treating glaucoma in a subject in need thereof, the method comprising topically administering to an eye of a patient an ophthalmic composition comprising: (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof; boric acid; and mannitol; wherein the composition has a pH from about 4.5 to about 5.2.


In some embodiments, provided herein are methods of treating glaucoma in a subject in need thereof, the method comprising topically administering to an eye of a patient an ophthalmic composition comprising: about 0.02% to about 0.03% weight/volume of (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof; about 4.7% weight/volume of mannitol; about 0.05% weight/volume of boric acid; and about 0.015% weight/volume of benzalkonium chloride; wherein the composition has a pH from about 4.5 to about 5.2.


In some embodiments, provided herein are methods of treating glaucoma in a subject in need thereof, the method comprising topically administering to an eye of a patient an ophthalmic composition comprising: (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof; boric acid; mannitol; and latanoprost.


In some embodiments, provided herein are methods of treating glaucoma in a subject in need thereof, the method comprising topically administering to an eye of a patient an ophthalmic composition comprising: mixture of (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof and (R)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof; boric acid; and mannitol; wherein the composition has a pH from about 4.5 to about 5.2.


In some embodiments, provided herein are methods of treating glaucoma in a subject in need thereof, the method comprising topically administering to an eye of a patient an ophthalmic composition comprising: about 0.02% to about 0.03% weight/volume of a mixture of (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof and (R)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof; about 4.7% weight/volume of mannitol; about 0.05% weight/volume of boric acid; and about 0.015% weight/volume of benzalkonium chloride; wherein the composition has a pH from about 4.5 to about 5.2.


In some embodiments, provided herein are methods of treating glaucoma in a subject in need thereof, the method comprising topically administering to an eye of a patient an ophthalmic composition comprising: a mixture of (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof and (R)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or a pharmaceutically acceptable salt thereof; boric acid; mannitol; and latanoprost.


4. EMBODIMENTS

Embodiment 1. An ophthalmic composition, comprising: 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.


Embodiment 2. The composition of embodiment 1, wherein the pH is from about 3.5 to about 5.5.


Embodiment 3. The composition of embodiments 1 or 2, wherein the pH is from about 4.5 to about 5.2.


Embodiment 4. The composition of any one of embodiments 1-3, further comprising a preservative.


Embodiment 5. The composition of embodiment 4, wherein the preservative comprises benzalkonium chloride.


Embodiment 6. The composition of any one of embodiments 1-5, further comprising an emulsifying agent.


Embodiment 7. The composition of embodiment 6, wherein the emulsifying agent comprises polyoxyl 40 stearate, polyethoxylated castor oil, or a combination thereof.


Embodiment 8. The composition of any one of embodiments 1-7, wherein the tonicity agent comprises mannitol.


Embodiment 9. The composition of any one of embodiments 1-8, wherein the buffer comprises boric acid or its salts.


Embodiment 10. The composition of any one of embodiments 1-9, further comprising water.


Embodiment 11. The composition of any one of embodiments 1-10, further comprising a pH adjusting agent.


Embodiment 12. The composition of any one of embodiments 1-11, wherein the 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate is a dimesylate salt.


Embodiment 13. The composition of any one of embodiments 1-12, wherein the 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts is (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts.


Embodiment 14. The composition of any one of embodiments 1-13, further comprising a second ophthalmic active compound.


Embodiment 15. The composition of embodiment 14, wherein the second ophthalmic active compound is a prostaglandin analog.


Embodiment 16. The composition of embodiment 15, wherein the prostaglandin analog is latanoprost or travoprost.


Embodiment 17. The composition of any one of embodiments 1-16, comprising about 0.02% w/v to about 0.03% w/v of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or it pharmaceutically acceptable salts.


Embodiment 18. The composition of any one of embodiments 1-17, comprising about 4.7% weight/volume of mannitol.


Embodiment 19. The composition of any one of embodiments 1-18, comprising about 0.05% weight/volume of boric acid.


Embodiment 20. The composition of any one of embodiments 1-19, comprising about 0.015% weight/volume of benzalkonium chloride.


Embodiment 21. The composition of embodiment 16, further comprising 0.005% weight/volume of latanoprost or travoprost.


Embodiment 22. An ophthalmic composition, comprising: (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; boric acid; and mannitol; wherein the composition has a pH from about 4.5 to about 5.2.


Embodiment 23. An ophthalmic composition comprising: about 0.02% to about 0.03% weight/volume of (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 4.7% weight/volume of mannitol; about 0.05% weight/volume of boric acid; and about 0.015% weight/volume of benzalkonium chloride; wherein the composition has a pH from about 4.5 to about 5.2.


Embodiment 24. An ophthalmic composition, comprising: (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; boric acid; mannitol; and latanoprost.


Embodiment 25. The compositions of any one of embodiments 22-24 wherein the salt is the dimesylate salt.


Embodiment 26. A method of treating an ophthalmic disease, the method comprising topically administering to the eye of a patient in need a composition of any one of claims 1-24.


Embodiment 27. The method of embodiments 26, wherein the ophthalmic disease is glaucoma.


5. EXAMPLES

The present disclosure has multiple aspects, illustrated by the following non-limiting examples. In the various examples, the below materials and characterization techniques have been used.


Example 1. Formulations of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate

Table 1 shows the composition of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate formulations. Formulations N, O, and P were prepared by adding boric acid, d-mannitol, and with or without 0.015% benzalkonium chloride in a labeled 150-milliliter (mL) plastic storage container. 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate dimesylate, with or without 5% benzalkonium chloride stock solution, was then added and dissolved by stirring the solution for another 10 minutes. 100 milliliter (mL) of purified water was then added to bring the solution almost to 100%, and the pH was adjusted to approximately 5.0. Sufficient 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate dimesylate (CAS number: #1422144-42-0) (0.0285% w/v) was added to have 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate free base (CAS number: #1254032-66-0) present at 0.02% w/v.










TABLE 1








Formulation (% weight/volume)










Ingredient
N
O
P













4-(3-amino-1-(isoquinolin-6-
0.02
0.02
0.04


ylamino)-1-oxopropan-2-





yl)benzyl 2,4-dimethylbenzoate





free base





Boric acid
0.05
0.05
0.05


D-mannitol
4.7
4.7
4.7


Benzalkonium chloride

0.015
0.015


Purified water
q.s.
q.s.
q.s.


pH
5.0
5.0
5.0









Example 2. Formulations of Fixed-Dose Combination of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate and Latanoprost

Table 2 shows the formulations of fixed-dose combination of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate and latanoprost. Formulations R and S were prepared by adding boric acid and d-mannitol in a labeled 150-milliliter (mL) plastic storage container. 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate and benzalkonium chloride/latanoprost stock solution (100×) were then added and dissolved by stirring the solution for another 10 minutes. 100 milliliter (mL) of purified water was then added to bring the solution almost to 100%, and the pH was adjusted to approximately 5.0. Sufficient 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate dimesylate (CAS number: #1422144-42-0) (0.0285% w/v) was added to have 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate free base (CAS number: #1254032-66-0) present at 0.02% w/v.










TABLE 2








Formulation (% weight/volume)









Ingredient
R
S












4-(3-amino-1-(isoquinolin-6-
0.02
0.02


ylamino)-1-oxopropan-2-




yl)benzyl 2,4-dimethylbenzoate




free base




Latanoprost
0.005
0.005


Boric acid
0.05
0.05


D-mannitol
4.7
4.7


Benzalkonium chloride
0.015
0.02


Purified water
q.s.
q.s.


pH
5.0
5.0









Example 3. Preservative-Free, Fixed-Dose Combination 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate and Latanoprost

Additional formulations may be prepared according to the method in Example 1. Table 3 shows the formulations of preservative-free, fixed-dose combination of 4-(3-amino-1-(isoquinolin-8-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate and latanoprost.










TABLE 3








Formulation (% weight/volume)










Ingredient
T
U
V













4-(3-amino-1-(isoquinolin-6-
0.02
0.02
0.02


ylamino)-1-oxopropan-2-





yl)benzyl 2,4-dimethylbenzoate





free base





Latanoprost
0.005
0.005
0.005


Boric acid
0.05
0.05
0.05


D-mannitol
4.7
4.7
4.7


Polyoxyl 40 stearate (Myrj-52)
0.5




Cremophor RH 40

0.25
0.5


Benzalkonium chloride





Purified water
q.s.
q.s.
q.s.


pH
5.5
5.5
5.5









Example 4. Formulations of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate

Table 4 shows compositions of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate formulations as its dimesylate and diHCI salts. Formulations N4 and 04 were prepared by adding boric acid, d-mannitol, and with or without 0.015% benzalkonium chloride in a labeled 150-milliliter (mL) plastic storage container. The disalts 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate mesylate (CAS number: #1422144-42-0), or 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate chloride (CAS number: #1253952-02-1), with or without 5% benzalkonium chloride stock solution, was then added and dissolved by stirring the solution for another 10 minutes. 100 milliliter (mL) of purified water was then added to bring the solution almost to 100%, and the pH was adjusted to approximately 5.0.


Formulation P4 may be prepared according to the process described herein.










TABLE 4








Formulation (% weight/volume)










Ingredient
N4
O4
P4













4-(3-amino-1-(isoquinolin-6-
0.0285
0.000
0.0143


ylamino)-1-oxopropan-2-





yl)benzyl 2,4-dimethylbenzoate





mesylate (disalt)





4-(3-amino-1-(isoquinolin-6-
0.000
0.0233
0.0116


ylamino)-1-oxopropan-2-





yl)benzyl 2,4-dimethylbenzoate





HCl (disalt)





Boric acid
0.05
0.05
0.05


D-mannitol
4.7
4.7
4.7


Benzalkonium chloride
0.015
0.015
0.008


Purified water
q.s.
q.s.
q.s.


pH
5.0
4.8
4.9









It is understood that the foregoing detailed description and accompanying examples are merely illustrative and are not to be taken as limitations upon the scope of the disclosure, which is defined solely by the appended claims and their equivalents.

Claims
  • 1. An ophthalmic formulation, consisting of: 0.0285 weight/volume % of a dimesylate salt of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate;0.05 weight/volume % of boric acid;4.7 weight/volume % of mannitol;water; anda pH of 5.
  • 2. The ophthalmic formulation of claim 1, wherein the 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate is (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate.
  • 3. The ophthalmic formulation of claim 1, wherein the mannitol is D-mannitol.
  • 4. The ophthalmic formulation of claim 1, which is a topical ophthalmic formulation.
  • 5. The ophthalmic formulation of claim 1, which is packaged in a unit dose form.
  • 6. The ophthalmic formulation of claim 1, which is packaged in a multidose form.
  • 7. The ophthalmic formulation of claim 1, which is in a plastic storage container.
  • 8. The ophthalmic formulation of claim 1, consisting of: 0.0285 weight/volume % of a dimesylate salt of (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate,0.05 weight/volume % of boric acid,4.7 weight/volume % of D-mannitol,water, anda pH of 5.
  • 9. A method of treating glaucoma in a subject in need thereof, comprising topically administering to an eye of the subject an ophthalmic formulation consisting of: 0.0285 weight/volume % of a dimesylate salt of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate,0.05 weight/volume % of boric acid,4.7 weight/volume % of mannitol,water, anda pH of 5.
  • 10. The method of claim 9, wherein the 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate is (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-di methyl benzoate.
  • 11. The method of claim 9, wherein the mannitol is D-mannitol.
  • 12. The method of claim 9, wherein the ophthalmic formulation is a topical ophthalmic formulation.
  • 13. The method of claim 9, wherein the ophthalmic formulation is packaged in a unit dose form.
  • 14. The method of claim 9, wherein the ophthalmic formulation is packaged in a multidose form.
  • 15. The method of claim 9, wherein the ophthalmic formulation is in a plastic storage container.
  • 16. The method of claim 9, wherein the ophthalmic formulation consists of: 0.0285 weight/volume % of a dimesylate salt of (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate,0.05 weight/volume % of boric acid,4.7 weight/volume % of D-mannitol,water, anda pH of 5.
RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 17/841,433, filed Jun. 15, 2022, which is a continuation of U.S. patent application Ser. No. 15/691,607, filed Aug. 30, 2017, which claims priority of U.S. Provisional Patent Application No. 62/382,237, filed Aug. 31, 2016, the entire content of each of which is incorporated herein by reference.

US Referenced Citations (144)
Number Name Date Kind
4146637 Metz et al. Mar 1979 A
4337256 Yasushi et al. Jun 1982 A
4456757 Hidaka et al. Jun 1984 A
4709032 Hidaka et al. Nov 1987 A
4911928 Wallach Mar 1990 A
4954512 Oguro et al. Sep 1990 A
5508288 Forbes et al. Apr 1996 A
5519036 Himmelsbach et al. May 1996 A
5770759 Ueno et al. Jan 1998 A
5798380 Kaufman et al. Aug 1998 A
5889052 Klimko et al. Mar 1999 A
5891646 Barak et al. Apr 1999 A
5977173 Wos et al. Nov 1999 A
5994397 Selliah et al. Nov 1999 A
6025392 Selliah et al. Feb 2000 A
6030999 Stjemschantz et al. Feb 2000 A
6037364 Burk Mar 2000 A
6037368 Selliah et al. Mar 2000 A
6048895 Wos et al. Apr 2000 A
6110693 Barak et al. Aug 2000 A
6110912 Kaufman et al. Aug 2000 A
6362177 Shiota et al. Mar 2002 B1
6586425 Kaufman et al. Jul 2003 B2
6699891 Kawaanishi et al. Mar 2004 B1
6787534 Haneda Sep 2004 B2
7268143 Jagtap et al. Sep 2007 B2
7329684 Mjalli et al. Feb 2008 B2
7345158 Egashira et al. Mar 2008 B2
7361678 Mjalli et al. Apr 2008 B2
7374891 Shahbaz May 2008 B2
7378498 Worley et al. May 2008 B2
7470787 deLong et al. Dec 2008 B2
7671205 deLong et al. Mar 2010 B2
8034943 deLong et al. Oct 2011 B2
8129411 Ehara et al. Mar 2012 B2
8278294 Plettenburg et al. Oct 2012 B2
8357699 deLong et al. Jan 2013 B2
8394826 deLong et al. Mar 2013 B2
8415372 Yamada et al. Apr 2013 B2
8450344 deLong et al. May 2013 B2
8455513 deLong et al. Jun 2013 B2
8455514 deLong et al. Jun 2013 B2
8455647 deLong et al. Jun 2013 B2
8716310 deLong et al. May 2014 B2
8759388 deLong et al. Jul 2014 B2
8809326 Bosanac et al. Aug 2014 B2
8871757 deLong et al. Oct 2014 B2
8921392 deLong et al. Dec 2014 B2
9096569 deLong et al. Aug 2015 B2
9255101 Berrebi-Bertrand et al. Feb 2016 B2
9365518 deLong et al. Jun 2016 B2
9415043 Kopczynski Aug 2016 B2
9512101 deLong et al. Dec 2016 B2
9643927 Sturdivant et al. May 2017 B1
9849122 Kopczynski et al. Dec 2017 B2
9884840 deLong et al. Feb 2018 B2
9890123 deLong et al. Feb 2018 B2
9931336 Kopczynski et al. Apr 2018 B2
9951059 deLong et al. Apr 2018 B2
9963432 Sturdivant et al. May 2018 B2
9993470 Kopczynski et al. Jun 2018 B2
10112920 deLong et al. Oct 2018 B2
10174017 deLong et al. Jan 2019 B2
10316029 deLong et al. Jun 2019 B2
10472327 deLong et al. Nov 2019 B2
10532993 deLong et al. Jan 2020 B2
10568878 Kopczynski et al. Feb 2020 B2
10588901 Kopczynski et al. Mar 2020 B2
10654844 deLong et al. May 2020 B2
10858339 deLong et al. Dec 2020 B2
10882840 deLong et al. Jan 2021 B2
10899714 deLong et al. Jan 2021 B2
11020385 Kopczynski et al. Jun 2021 B2
11021456 deLong et al. Jun 2021 B2
11028081 deLong et al. Jun 2021 B2
11185538 Kopczynski et al. Nov 2021 B2
11197853 Kopczynski et al. Dec 2021 B2
11312700 deLong et al. Apr 2022 B2
11389441 Lin et al. Jul 2022 B2
20040091946 Oakley et al. May 2004 A1
20040157859 Wu et al. Aug 2004 A1
20040176462 Kawanishi et al. Sep 2004 A1
20050032125 Oakley et al. Feb 2005 A1
20050054558 Benowitz Mar 2005 A1
20050176712 Wakabayashi et al. Aug 2005 A1
20050245509 Nakajima et al. Nov 2005 A1
20050282805 Hangeland et al. Dec 2005 A1
20060270670 Chew et al. Nov 2006 A1
20070111983 Fong May 2007 A1
20070123561 Lee et al. May 2007 A1
20070129404 Hagihara et al. Jun 2007 A1
20070135499 deLong et al. Jun 2007 A1
20070149473 Chatterton et al. Jun 2007 A1
20070149548 Hellberg et al. Jun 2007 A1
20070167444 Kuramochi et al. Jul 2007 A1
20070203174 Klimko et al. Aug 2007 A1
20070238741 Nagarathnam et al. Oct 2007 A1
20080021026 Kahraman et al. Jan 2008 A1
20080021217 Borchardt Jan 2008 A1
20080058384 Lee et al. Mar 2008 A1
20080096238 Sharif et al. Apr 2008 A1
20080125427 Sehon et al. May 2008 A1
20080139595 Schirok et al. Jun 2008 A1
20080153799 Laurent et al. Jun 2008 A1
20080153813 Chen et al. Jun 2008 A1
20080161297 Bosanac et al. Jul 2008 A1
20080194584 Birault et al. Aug 2008 A1
20080275029 Berdini et al. Nov 2008 A1
20080287516 Wu et al. Nov 2008 A1
20090005321 Zimmer et al. Jan 2009 A1
20090069371 deLong et al. Mar 2009 A1
20090143381 Ruah et al. Jun 2009 A1
20100004239 Tang et al. Jan 2010 A1
20100056568 Plettenburg et al. Mar 2010 A1
20100063025 Plettenburg et al. Mar 2010 A1
20100093790 deLong et al. Apr 2010 A1
20100105650 Plettenburg et al. Apr 2010 A1
20110015204 Bencsik et al. Jan 2011 A1
20110039893 Kori et al. Feb 2011 A1
20120040994 Nakajima et al. Feb 2012 A1
20120135984 deLong et al. May 2012 A1
20120322871 Mercier Dec 2012 A1
20130296363 Faraoni et al. Nov 2013 A1
20130310370 Mizuno Nov 2013 A1
20130318457 Bjorklund Nov 2013 A1
20140187617 deLong et al. Jul 2014 A1
20140275160 Kopczynski Sep 2014 A1
20140275161 Kopczynski Sep 2014 A1
20140288086 Cui et al. Sep 2014 A1
20140357652 Bosanac et al. Dec 2014 A1
20150175534 Harvey et al. Jun 2015 A1
20150175549 deLong et al. Jun 2015 A1
20150266881 Tomita et al. Sep 2015 A1
20150297581 Bosanac et al. Oct 2015 A1
20160016951 Schiemann et al. Jan 2016 A1
20160243102 Bosanac et al. Aug 2016 A1
20160272589 deLong et al. Sep 2016 A1
20170000819 Capriotti et al. Jan 2017 A1
20190322625 deLong et al. Oct 2019 A1
20200102290 deLong et al. Apr 2020 A1
20200276179 Kopczynski et al. Sep 2020 A1
20210253547 deLong et al. Aug 2021 A1
20210363141 deLong et al. Nov 2021 A1
20220088000 Kopczynski et al. Mar 2022 A1
Foreign Referenced Citations (104)
Number Date Country
0109023 May 1984 EP
0232569 Aug 1987 EP
0389995 Oct 1990 EP
0482939 Apr 1992 EP
1541151 Jun 2005 EP
1550660 Jul 2005 EP
2005227441 Aug 2005 JP
2007236388 Sep 2007 JP
2007246466 Sep 2007 JP
2013-35802 Feb 2013 JP
2014-19650 Feb 2014 JP
1988003137 May 1988 WO
1993018028 Sep 1993 WO
1995019964 Jul 1995 WO
1996010407 Apr 1996 WO
1997023223 Jul 1997 WO
1998012175 Mar 1998 WO
1998020880 May 1998 WO
1998020881 May 1998 WO
1998021180 May 1998 WO
1998021181 May 1998 WO
1998021182 May 1998 WO
1998039293 Sep 1998 WO
1988050024 Nov 1998 WO
1998057930 Dec 1998 WO
1998057942 Dec 1998 WO
1999002165 Jan 1999 WO
1999012895 Mar 1999 WO
1999012896 Mar 1999 WO
1999012898 Mar 1999 WO
1999025358 May 1999 WO
1999026629 Jun 1999 WO
1999032441 Jul 1999 WO
2000003736 Jan 2000 WO
2000003980 Jan 2000 WO
2000071508 Nov 2000 WO
2000076970 Dec 2000 WO
2001037826 May 2001 WO
2001047891 Jul 2001 WO
2001053268 Jul 2001 WO
2001053274 Jul 2001 WO
2001056607 Aug 2001 WO
2002022576 Mar 2002 WO
2002032864 Apr 2002 WO
2002085857 Oct 2002 WO
2002085859 Oct 2002 WO
2003064397 Aug 2003 WO
2003068749 Aug 2003 WO
2003073999 Sep 2003 WO
2003080578 Oct 2003 WO
2004029045 Apr 2004 WO
2004078747 Sep 2004 WO
2005020921 Mar 2005 WO
2005035503 Apr 2005 WO
2005037257 Apr 2005 WO
2006041119 Apr 2006 WO
2006051290 May 2006 WO
2006062982 Jun 2006 WO
2006076706 Jul 2006 WO
2007008926 Jan 2007 WO
2007008942 Jan 2007 WO
2007060028 May 2007 WO
2007065916 Jun 2007 WO
2007076360 Jul 2007 WO
2007076367 Jul 2007 WO
2007100880 Sep 2007 WO
20070142323 Dec 2007 WO
2008011557 Jan 2008 WO
2008011560 Jan 2008 WO
2008016016 Feb 2008 WO
2008036459 Mar 2008 WO
2008036540 Mar 2008 WO
2008049000 Apr 2008 WO
2008049919 May 2008 WO
2008054999 May 2008 WO
2008077057 Jun 2008 WO
2008077550 Jul 2008 WO
2008077551 Jul 2008 WO
2008077552 Jul 2008 WO
2008077553 Jul 2008 WO
2008077554 Jul 2008 WO
2008077555 Jul 2008 WO
2008077556 Jul 2008 WO
2008079880 Jul 2008 WO
2008079945 Jul 2008 WO
2008086269 Jul 2008 WO
2008124665 Oct 2008 WO
2009091898 Jul 2009 WO
2010011853 Jan 2010 WO
2010019903 Feb 2010 WO
2010126626 Nov 2010 WO
2010127329 Nov 2010 WO
2010127330 Nov 2010 WO
2010146881 Dec 2010 WO
2011085351 Jul 2011 WO
2012063237 May 2012 WO
2012105674 Aug 2012 WO
2014144781 Sep 2014 WO
2016123627 Aug 2016 WO
2018034702 Feb 2018 WO
2018045091 Mar 2018 WO
2018183911 Oct 2018 WO
2019191654 Oct 2019 WO
2020056345 Mar 2020 WO
Non-Patent Literature Citations (218)
Entry
United States Patent Office Notice of Allowance for U.S. Appl. No. 13/442,263 dated Apr. 15, 2014 (8 pages).
United States Patent Office Action for U.S. Appl. No. 13/442,263 dated Dec. 19, 2012 (13 pages).
European Search Report for European Patent Application No. 18206195.2 dated Feb. 11, 2019 (10 pages).
United States Patent Office Action for U.S. Appl. No. 13/442,263 dated Jun. 12, 2013 (17 pages).
United States Patent Office Notice of Allowance for U.S. Appl. No. 13/723,811 dated Aug. 19, 2014 (11 pages).
United States Patent Office Notice of Allowance for U.S. Appl. No. 13/768,594 dated Oct. 29, 2013 (7 pages).
United States Patent Office Notice of Allowance for U.S. Appl. No. 14/213,961 dated Jun. 20, 2016 (8 pages).
United States Patent Office Notice of Allowance for U.S. Appl. No. 14/273,895 dated Apr. 1, 2015 (8 pages).
United States Patent Office Notice of Allowance for U.S. Appl. No. 14/583,439 dated Feb. 12, 2016 (8 pages).
United States Patent Office Notice of Allowance for U.S. Appl. No. 14/790,376 dated Aug. 2, 2016 and supplemental Notice of Allowability dated Aug. 19, 2016 (10 pages).
Yamashita et al., “The therapeutic effects of Rho-Rock inhibitors on CNS disorder,” Therapeutics and Clinical Risk Management, 2008, vol. 4, pp. 605-615.
International Search Report and Written Opinion dated Aug. 23, 2018 for International Application No. PCT/US2018/025494 filed on Mar. 30, 2018.
Westra et al., “p38 Mitogen-Activated Protein Kinase (MAPK) in Rheumatoid Arthritis.” Mini-Reviews in Medicinal Chemistry (2006) 6(8):867-874.
Westaway et al., “N-tetrahydroquinolinyl, N-quinolinyl and N-isoquinolinyl biaryl carboxamides as antagonists of TRPV1.” Biorg. Med. Chem. Lett. (2006) 16:4533-4536.
Van Muijl Wijk-Koezen et al., “A novel class of adenosine A3 receptor-ligands. 2. Structure affinity profile of a series of isoquinoline and quinazoline compounds.” J. Med. Chem. ( 1998) 41:3994-4000.
Vippagunta et al., “Cystalline solids.” Advanced Drug Delivery Reviews, 48:3-26 (2001).
Wallach and Philippot, “New Type of Lipid Vesicle: Novasome®”, Liposome Technology, vol. 1, pp. 141-156 (1993).
Webster, F.X. et al., “Following the Course of Resolution of Carboxylic Acids by 13C NMR Spectrometry of Amine Salts” J. Org. Chem. (1982) 47(26):5225-5226.
West, A.R., “Solid state chemistry and its applications,” Wiley, New York (1988) pp. 358 and 365.
International Search Report and Written Opinion dated Nov. 15, 2019, for International Patent Application Serial No. PCT/US2019/051136 filed on Sep. 13, 2019.
Donegan et al., Discovery of molecular therapeutics for glaucoma: Challenges, successes, and promising directions. Journal of Medicinal Chemistry, vol. 59, Issue 3, pp. 788-809 (2016).
International Search Report and Written Opinion dated Jul. 25, 2019, for International Patent Application Serial No. PCT/US2019/024954 filed on Mar. 29, 2019.
Bhatia et al., A review on Bioisosterism: A Rational approach for drug design and molecular modification. Pharmacologyonline, 1:272-299 (2011).
Gould, Philip L., Salt selection for basic drugs. International Journal of Pharmaceutics, vol. 33, pp. 201-217 (1986).
Williams et al., Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am. J. Ophthalmol., vol. 152, pp. 834-841 (2011).
Yingling et al., ARVO Annual Meeting Abstract, Apr. 2009, IOP-Lowering Efficacy and Tolerability of AR-12286, a Potent Kinase Inhibitor for the Treatment of Glaucoma. Investigative Ophthalmology & Visual Science, Apr. 2009, vol. 50, 4063 (2009).
Rowe et al., Boric Acid. Handbook of Pharmaceutical Excipients, Fifth Edition (2006). Pharmaceutical Press and American Pharmacists Association.
Elder et al., Review: The utility of sulfonate salts in drug development. Journal of Pharmaceutical Sciences, 99 (7):2948-2961 (2010).
U.S. Appl. No. 17/841,433, filed Jun. 15, 2022.
U.S. Appl. No. 17/722,832, filed Apr. 18, 2022.
Extended European Search Report, dated Apr. 30, 2021, for European Patent Application Serial No. 20203979.8.
Salt selection in drug development. PharmTech.com (2008) accessed May 6, 2020.
Extended European Search Report, dated Mar. 29, 2021, for European Patent Application Serial No. 20207657.6.
United States Patent Notice of Allowability for U.S. Appl. No. 11/621,887 dated Oct. 29, 2010 (14 pages).
United States Patent Office Action for U.S. Appl. No. 11/856,740 dated Aug. 16, 2013 (14 pages).
United States Patent Office Action for U.S. Appl. No. 11/856,740 dated Dec. 6, 2010 (12 pages).
United States Patent Office Action for U.S. Appl. No. 11/856,740 dated Jun. 29, 2010 (10 pages).
United States Notice of Allowance for U.S. Appl. No. 12/009,326 dated Feb. 3, 2011 (8 pages).
United States Patent Office Action for U.S. Appl. No. 12/180,259 dated Jul. 5, 2011 (11 pages).
United States Patent Office Action for U.S. Appl. No. 12/639,670 dated Jan. 31, 2011 (8 pages).
United States Patent Office Action for U.S. Appl. No. 12/639,670 dated Jul. 27, 2011 (5 pages).
United States Patent Office Action for U.S. Appl. No. 12/694,965 dated May 17, 2012 (13 pages).
United States Patent Office Action for U.S. Appl. No. 12/701,963 dated May 10, 2011 (3 pages).
United States Patent Office Action for U.S. Appl. No. 12/704,822 dated Apr. 30, 2012 (34 pages).
United States Patent Office Action for U.S. Appl. No. 12/704,822 dated May 8, 2014 (13 pages).
United States Patent Office Action for U.S. Appl. No. 12/704,822 dated Oct. 10, 2013 (11 pages).
United States Patent Office Action for U.S. Appl. No. 13/017,708 dated Apr. 3, 2012 (11 pages).
United States Patent Office Action for U.S. Appl. No. 13/230,105 dated Mar. 5, 2012 (8 pages).
United States Patent Office Action for U.S. Appl. No. 13/318,457 dated Jun. 6, 2013 (12 pages).
United States Patent Office Action for U.S. Appl. No. 13/723,811 dated Jan. 27, 2014 (8 pages).
United States Patent Office Action for U.S. Appl. No. 13/723,811 dated Jun. 17, 2014 (6 pages).
United States Patent Office Action for U.S. Appl. No. 13/768,594 dated Jul. 10, 2013 (14 pages).
United States Patent Office Action for U.S. Appl. No. 14/138,592 dated Dec. 9, 2014 (14 pages).
United States Patent Office Action for U.S. Appl. No. 14/138,592 dated Jul. 28, 2014 (17 pages).
United States Patent Office Action for U.S. Appl. No. 14/213,940 dated Oct. 29, 2015 (33 pages).
United States Patent Office Action for U.S. Appl. No. 14/213,961 dated Oct. 30, 2015 (37 pages).
United States Patent Office Action for U.S. Appl. No. 14/273,895 dated Aug. 20, 2014 (8 pages).
United States Patent Office Action for U.S. Appl. No. 14/273,895 dated Dec. 24, 2014 (7 pages).
United States Patent Office Action for U.S. Appl. No. 14/461,597 dated Jan. 30, 2015 (19 pages).
United States Patent Office Action for U.S. Appl. No. 14/583,439 dated Jun. 23, 2015 (6 pages).
United States Patent Office Action for U.S. Appl. No. 14/583,439 dated Oct. 30, 2015 (7 pages).
United States Patent Office Action for U.S. Appl. No. 14/641,962 dated Sep. 22, 2015 (16 pages).
United States Patent Office Action for U.S. Appl. No. 14/754,787 dated Oct. 30, 2015 (20 pages).
United States Patent Office Action for U.S. Appl. No. 14/790,376 dated Jan. 22, 2016 (14 pages).
United States Patent Office Action for U.S. Appl. No. 15/076,216 dated Sep. 1, 2016 (6 pages).
United States Patent Office Advisory Action for U.S. Appl. No. 11/856,740 dated Feb. 10, 2011 (3 pages).
United States Patent Office Final Rejection for U.S. Appl. No. 12/704,822 dated Jan. 16, 2013 (16 pages).
United States Patent Office Final Rejection for U.S. Appl. No. 13/230,105 dated Jul. 9, 2012 (11 pages).
United States Patent Office Final Rejection for U.S. Appl. No. 13/318,457 dated Nov. 27, 2013 (13 pages).
United States Patent Office Final Rejection for U.S. Appl. No. 13/442,263 dated Dec. 6, 2013 (8 pages).
United States Patent Office Notice of Allowability for U.S. Appl. No. 13/017,708 dated Dec. 12, 2012 (5 pages).
United States Patent Office Notice of Allowance for U.S. Appl. No. 11/621,887 dated Feb. 27, 2013 (8 pages).
United States Patent Office Notice of Allowance for U.S. Appl. No. 11/856,740 dated Apr. 1, 2014 (8 pages).
United States Patent Office Notice of Allowance for U.S. Appl. No. 12/009,326 dated Feb. 25, 2013 (8 pages).
United States Patent Office Notice of Allowance for U.S. Appl. No. 12/009,326 dated Jan. 6, 2012 (5 pages).
United States Patent Office Notice of Allowance for U.S. Appl. No. 12/180,259 dated Dec. 19, 2011 (6 pages).
United States Patent Office Notice of Allowance for U.S. Appl. No. 12/180,259 dated Feb. 25, 2013 (8 pages).
United States Patent Office Notice of Allowance for U.S. Appl. No. 12/694,965 dated Nov. 19, 2012 (4 pages).
United States Patent Office Notice of Allowance for U.S. Appl. No. 12/694,965 dated Nov. 2, 2012 (8 pages).
United States Patent Office Notice of Allowance for U.S. Appl. No. 12/704,822 dated Sep. 9, 2014 (11 pages).
United States Patent Office Notice of Allowance for U.S. Appl. No. 13/017,708 dated Oct. 23, 2012 (7 pages).
United States Patent Office Notice of Allowance for U.S. Appl. No. 13/017,708 dated Sep. 17, 2012 (8 pages).
United States Patent Office Notice of Allowance for U.S. Appl. No. 13/230,105 dated Mar. 19, 2013 (5 pages).
Berge et al, 1977, “Pharmaceutically Acceptable Salts.” J. Pharm. Sci. vol. 66, pp. 1-19.
Bird, G.J. et al., “N-methyl as a bioisostere for the oxygen link between the aromatic rings of aryloxyphenoxypropionate herbicides,” Bioorg. Med. Chem. Lett. (1997) 7:1489-1492.
Blough BE, Keverline KI, Nie Z, Navarro H, Kuhar MJ, Carroll FI (2002). “Synthesis and transporter binding properties of 3beta-[4′-(phenylalkyl, phenylalkenyl, and phenylalkynyl) phenyltropane]-2beta-carboxylic acid methyl esters: evidence of a remote phenyl binding domain on the dopamine transporter”. J. Med. Chem. 45 (18):4029-37.
C.T.F.A. Cosmetic Ingredient Handbook, “Surfactants—Emulsifying Agents”, Second Edition, The Cosmetic, Toiletry, and Fragrance Association, New York, Wenninger, J.A. et al., eds. (1992) 587-592.
Calmes et al., Asymmetric Synthesis of (S)-beta∧2-Homoarylglycines. Eur. J. Org. Chem. 2000, 2459-2466.
Canadian Patent Office Action for Application No. 2,731,869 dated Jun. 9, 2015 (3 pages).
Canadian Patent Office Action for Application No. 2,731,869 dated Feb. 18, 2016 (4 pages).
Canadian Patent Office Action for Application No. 2,760,562 dated Feb. 2, 2015 (4 pages).
Canadian Patent Office Action for Application No. 2,760,562 dated Jul. 3, 2015 (3 pages).
Canadian Patent Office Action for Application No. 2,712,443 dated Dec. 27, 2013 (3 pages).
Capdeville, R. et al., “Glivec (STI571, IMATINIB), A Rationally Developed, Targeted Anticancer Drug”, Nature Reviews Drug Discovery (2002) 1:493-502.
Chen, P. et al., “Identification of novel and potent isoquinoline aminooxazole-based IMPDH inhibitors,” Bioorg. Med. Chem. Lett. (2003) 13(7):1345-1348.
Cheung et al., N-methylamino acids in peptide synthesis. V. The syntesis of N-tert-butyloxycarbonyl, N-methylamino acids by N-methylation. Can. J. Chem. 1977, 55,906-910.
International Search Report and Written Opinion for International Application No. PCT/US2017/025609 dated Jul. 3, 2017 (8 pages).
International Search Report and Written Opinion for International Application No. PCT/US2017/065631 dated Feb. 13, 2018 (6 pages).
Ito, N. et al., “A medium-term rat liver bioassay for rapid in vivo detection of carcinogenic potential of chemicals,” Cancer Science, Jan. 2003, vol. 94, No. 1, pp. 3-8.
Jacobs, M. et al., “The structure of dimeric ROCK I reveals the mechanism for ligand selectivity,” J. Bio. Chem., 2006, pp. 260-268, published on Jan. 6, 2006.
Japanese Patent Office Action for Application No. 2009-545622 dated Mar. 1, 2013 (8 pages—including English Translation).
Japanese Patent Office Action for Application No. 2009-545622 dated Oct. 21, 2013 (8 pages—Including English Translation).
Japanese Patent Office Action for Application No. 2010-543237 dated Aug. 8, 2013 (10 pages—Including English Translation).
Japanese Patent Office Action for Application No. 2010-543237 dated Jan. 8, 2014 (2 pages—Including English Translation).
Japanese Patent Office Action for Application No. 2011-520203 dated Jan. 28, 2014 (8 pages, English translation included).
Japanese Patent Office Action for Application No. 2012-508492 dated Apr. 2, 2015 (4 pages, English translation included).
Japanese Patent Office Action for Application No. 2012-508492 dated Apr. 7, 2014 (5 pages, English translation only).
Japanese Patent Office Action for Application No. 2014-131231 dated Jan. 14, 2015 (8 pages, English translation attached).
Japanese Patent Office Action for Application No. 2014-131231 dated Jan. 27, 2016 (3 pages, English translation only).
Japanese Patent Office Action for Application No. 2015-216395 dated Nov. 14, 2016 (7 pages including translation).
Karaman, M.W. et al., “A quantitative analysis of kinase inhibitor selectivity,” Nature Biotech. (2008) 26(1):127-132.
Katritzky, A.R. et al., “Benzotriazole mediated amino-, amide-, alkoxy- and alkylthio-alkylation,” Tetrahedron (2005) 61:2555-2581.
Kumar et al., Catalyst-free water mediated reduction of nitroarenes using glucose as a hydrogen source. RSC Advances, 3:4894-4898 (2013).
Lala, P .K. et al., “Role of nitric oxide in tumor progression: lessons from experimental tumors,” Cancer and Metastasis Reviews (1998) 17:91-106.
Liljebris, C. et al., “Derivatives of 17-Pheny 1-18,19 ,20-trinorprostaglandin F2a Isopropyl Ester: Antiglaucoma Agents,” J. Med. Chem. (1995) 38(2):289-304.
Loge et al., Synthesis and pharmacological study of rho-kinase inhibitors: Pharmacomodulations on the lead compound Fasudil. J. of Enzy Inhib & Med Chem, 2003,18(2),127-128.
Matsui et al., “Novel 5-HT3 antagonists. Isoquinolinones and 3-aryl-2-pyridones.” J. Med. Chem. (1992) 35:3307-3319.
McCutcheon's, “Emulsifiers & Detergents”, North American Edition (1994) vol. 1:236-239.
Meanwell, “Synopsis of some recent tactocal application of bioisosteres in drug design,” J. Med. Chem., 2011, vol. 54, pp. 2529-2591.
Nakanishi et al., Effects of protein kinase inhibitors and protein phosphatase inhibitors on cyclic AMP-dependent down-regulation of vesicular monoamine transport in pheochromocytoma PC12 cells. FEBS Letters 368, (1995) 411-414.
Oakley et al., “The Cellular Distribution of Fluorescently Labeled Arrestins Provides a Robust, Sensitive and Universal Assay for Screening G Protein-Coupled Receptors.” Assay and Drug Development Technologies vol. 1, No. 1-1:21-30 (2002).
Olson, “Application for ROCK kinase inhibition,” Current Opinion in Cell Biology, 2008, vol. 20, pp. 242-248.
Parang et al., “Design strategies for protein kinase inhibitors.” Curr. Opin. In Drug Disc. & Dev. (2004) 7(5):617-629.
Pardridge, “The Blood-Brain Barrier: Bottleneck in Brain Drug development,” J. Am. Soc. Exper. NeuroTherapeutics, 2005, vol. 2, p. 3-14.
Partial International Search Report and Invitation to pay Additional Fees for Application No. PCT/US2009/031117 dated Apr. 16, 2009 ( 4 pages).
Penmetsa et al., Development of Reversed-Phase Chiral HPLC Methods Using Mass Spectrometry Compatible Mobile Phases. J. Liquid Chroma. & Rel. Tech. 23(6):831-839 (2000).
Penn et al., “Pharmacological Inhibition of Protein Kinases in Intact Cells: Antagonism of Beta Adrenergic Receptor Ligand Binding by H-89 Reveals Limitations of Usefulness.” J. Pharm. Exp. Ther. 288(2):428-437 (1999).
Pharmasolve (N-Methyl-2-Pyrrolidone) product spcification, International Specialty Products, 2000, 10 pages.
Poradowska et al., The Preparation of 6-Aminoisoquinoline. Synthesis 11:733, 1975.
PubChem, AC1 NQAJU (compound sumary for CID 5172372) ‘372’ date created: Sep. 26, 2005 date access: Jan. 5, 2016, 10 pages.
Rashid et al., “Development of Rho-kinase inhibitors for cardiovascular medicine,” Trends in Pharmacological Science, 2007, vol. 28, pp. 296-302.
Shankar et al., “Protein-kinase-specific inhibitors block Langerhans' cell migration by inhibiting interleukin-1alpha release.” Immunology (1999) 96:230-235.
Sharma et al., Highly Chemo- and Regioselective Reduction of Aromatic Nitro Compounds Catalyzed by Recyclable Copper(II) as well as Cobalt(II) Phthalocyanines. Advanced Synthesis and Catalysis, 352:1834-1840 (2010).
Sharma et al., Zinc phthalocyanine with PEG-400 as a recyclable catalytic system for selective reduction of aromatic nitro compounds. Green Chem., 14:2289-2293 (2012).
Sharma et al., Phosphane-Free Green Protocol for Selective Nitro Reduction with an Iron-Based Catalyst. Chem. Eur. J., 17:5903-5907 (2011).
Stirewalt et al., “The Role of FLT3 In Haematopoietic Malignancies.” Nature Reviews Cancer (2003) 3:650-665.
STN Registry Database entry for CAS RN 309930-43-6, Published in database Dec. 20, 2000.
Sturdivant et al., Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma. Bioorganic & Medicinal Chemistry Letters, 26:2475-2480 (2016).
Sturdivant et al., Identification of intermediates in the stepwise reduction of 1,3-dichloro-6nitroisoquinoline to 6-aminoisiquinoline. 248th National Meeting of the American Chemical Society, Aug. 2014, MEDI 153.
Tamura, M., et al., “Development of specific Rho-kinase inhibitors and their clinical application,” Biochimica et Biophysica Acta, 2005, vol. 1754, pp. 245-252.
Torres, G.E. et al. (2003). “Plasma membrane monoamine transporters: structure, regulation and function”. Nat. Rev. Neurosci. 4 (1): 13-25.
United States Office Action for U.S. Appl. No. 11/485,182 dated Apr. 16, 2009 (13 pages).
United States Office Action for U.S. Appl. No. 11/621,892 dated Aug. 8, 2008 (9 pages).
United States Office Action for U.S. Appl. No. 11/621,892 dated Mar. 9, 2009 (6 pages).
United States Office Action for U.S. Appl. No. 12/274,887 dated Jun. 16, 2009 (11 pages).
United States Patent Office Action for U.S. Appl. No. 11/621,887 dated May 18, 2010 (8 pages).
“Cancer”, MedlinePlus (retrieved Jul. 6, 2007) 10 pages, http://www.nlm.nih.gov/medlineplus/cancer.html.
Anonymous, “Aerie Pharmaceuticals, Inc. Gets Good News on Glaucoma Treatment” (Feb. 11, 2012) Retrieved from the Internet: URL:http://www.biospace.com.
Australian Patent Examination Report No. 1 for Application No. 2009206075 dated Jan. 29, 2013 (3 pages).
Australian Patent Examination Report for Application No. 2016201754 dated Oct. 19, 2016 (4 pages).
Australian Patent Examination Report No. 1 for Application No. 2010241996 dated Apr. 1, 2015 (4 pages).
Australian Patent Office Action for Application No. 2010241996 dated Mar. 21, 2016 (3 pages).
Banker, G.S. et al., Modern Pharmaceutics, Marcel Dekker, Inc., New York, (1979) Chapters 9 and 10.
Basu et al., Ultrasound-promoted highly efficient reduction of aromatic nitro compounds to the aromatic amines by samarium/ammonium chloride. Tetrahedron Letters, 41:5603-5606 (2000).
Chinese Patent Office Action for Application No. 201480027763.3 dated Nov. 1, 2016 (18 pages including translation).
Dancey, J. et al., “Issues and Progress with Protein Kinase Inhibitors for Cancer Treatment”, Nature Reviews Drug Discovery (2003) 2:296-313.
DeLong et al., “Discovery and SAR of a Class of Oculary-active Compounds Displaying a Dual Mechanism of Activity for the Treatment of Glaucoma” (May 6-10, 2012) Retrieved from the Internet:URL:http://www.aeriepharma.com.
Dorwald, F.Z., Side Reactions in Organic Synthesis. A Guide to Successful Synthesis Design, Wiley-VCH, Weinheim (2005) IX of Preface and 1-15.
Dowton et al., “Influence of Liposomal Composition on Topical Delivery of Encapsulated Cyclosporin A”, S.T.P. Pharma Sciences, vol. 3, pp. 404-407 (1993).
Ehara et al., Structure-based design of substituted piperidines as a new class of highly efficacious oral direct renin inhibitors. ACS Medicinal Chemistry Letters, 5(7):787-792 (2014).
Ehara, abstract only, CA 161:93707 (2014).
European Patent Office Action for Application No. 08713603.2 dated Aug. 14, 2012 (3 pages).
European Patent Office Action for Application No. 08713603.2 dated Nov. 21, 2013 (4 pages).
European Patent Office Action for Application No. 09702189.3 dated Feb. 1, 2011 (5 pages).
European Patent Office Action for Application No. 09702189.3 dated Dec. 28, 2011 (5 pages).
European Patent Office Action for Application No. 09790775.2 dated Oct. 24, 2011 (5 pages).
European Patent Office Search Report for Application No. 15002893.4 dated Jun. 27, 2016 (5 pages).
Extended European Search Report for European Patent Application No. 12007093.3 dated Nov. 23, 2012 (5 pages).
European Patent Office Action for Application No. 12007093.3 dated Mar. 26, 2014 (4 pages).
European Patent Office Action for Application No. 12007093.3 dated Aug. 23, 2013 (5 pages).
European Patent Office Action for Application No. 12007092.5 dated Nov. 23, 2012 (5 pages).
Extended European Search Report for European Patent Application No. 12007089.1 dated Nov. 23, 2012 (5 pages).
European Search Report for European Application No. 18160338.2 dated May 25, 2018 (6 pages).
Examination Report from the Australian Patent Office for Application No. 2008205047 dated Nov. 26, 2012 (6 pages).
Examination Report from the Australian Patent Office for Application No. 2009273932 dated Mar. 13, 2013 (3 pages).
Examination Report from the Australian Patent Office for Application No. 2009273932 dated Jun. 6, 2014 (2 pages).
Fox et al., 19F and 13C GIAO-NMR chemical shifts for the identification of perfluoro-quinoline and -isoquinoline derivatives. Journal of Fluorine Chemistry, 155, pp. 62-71 (2013).
Foye, Foye's Principles of Medicinal Chemistry, 5th Edition (2002) Lippencott, Williams, Wilkins, p. 59-63.
Gingras et al., “In Synthesis and evaluation of 4-(1-aminoalkyl)-N-(4-pyridyl)-cyclohexanecarboxamides as Rho-kinase inhibitors and neurite outgrowth promoters,” Bioorganic & Medicinal Chemistry Letters, 2004, vol. 14, pp. 4931-4934.
Golub, T.R. et al., “Molecular classification of cancer: class discovery and class prediction by gene expression monitoring,” Science (1999) 286:531-537.
Guha et al., Solid supported rhodium(0) nanoparticles: an efficient catalyst for chemo- and regio-selective transfer hydrogenation of nitroarenes to anilines under microwave irradiation. Tetradedron Letters, 55:2912-2916 (2014).
Hackam, A.S. et al., “The Wnt Signaling Pathway in Retinal Degenerations”, IUBMB Life (2005) 57(6):381-388.
Hazeldine, S.T. et al., “II Synthesis and biological evaluation of some bioisosteres and cogeners of the anti tumour agent, 2{ 4[7-chloro-2-quinoxalinyl)oxy ]phenoxy }propionic acid (XK469),” J. Med. Chem. (2002) 45:3130-3137.
He et al., “Further structure-activity relationship studies of piperidine-based monoamine transporter inhibitors: effects of piperidine ring stereochemistry on potency. Identification of norepinephrine transporter selective ligands and broad-spectrum transporter inhibitors”. J. Med. Chem. 48 (25): 7970-9 (2005).
Helal, C.J. et al., “Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease,” Bioorg. Med. Chem. (2004) 14(22):5521-5525.
Helzner, “Bright New Ideas in Glaucoma Treatment” (2013) Retreived from the Internet: URL:http://mydigimag.rrd.com. [Ophthalmology Management, vol. 17, Issue: Jan. 2013, pp. 54-56].
Hu, E. et al., “Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges,” Exp. Opin. Ther. Targets (2005) 9:715-736.
Inouye, Y. et al., “The Absolute Configurations of TRANS-1,2 Cyclopropanedicarboxylic Acid and TRANS-2-Phenylcyclopropanecarboxylic Acid”, Int'l. J. Org. Chem. (1964) 20(5):1695-1699.
International Search Report and Written Opinion for Application No. PCT/US2015/61177 dated Feb. 2, 2016 (16 pages).
International Preliminary Examination Report for Application No. PCT/US2006/026947 dated Jan. 24, 2008 (10 pages).
International Preliminary Report on Patentability for Application No. PCT/US08/50374 dated Jul. 14, 2009 (12 pages).
International Search Report and Written Opinion for Application No. PCT/US2006/026976 dated Feb. 15, 2007 (14 pages).
International Search Report and Written Opinion for Application No. PCT/US2007/078343 dated Apr. 15, 2008 (12 pages).
International Search Report and Written Opinion for Application No. PCT/US2009/031117 dated Sep. 24, 2009 (13 pages).
International Search Report and Written Opinion for Application No. PCT/US2009/051569 dated May 20, 2010 (11 pages).
International Search Report and Written Opinion for Application No. PCT/US2010/022246 dated Nov. 10, 2010 (7 pages).
International Search Report and Written Opinion for Application No. PCT/US2010/33316 dated Jul. 14, 2010 (10 pages).
International Search Report and Written Opinion for Application No. PCT/US2010/33317 dated Aug. 17, 2010 (10 pages).
International Search Report and Written Opinion for Application No. PCT/US2014/029335, dated Jul. 2, 2014 (11 pages).
Al-Rashida et al., Diarylsulfonamides and their bioisosteres as dual inhibitors of alkaline phosphatase and carbonic anhydrase: Structure activity/relationship and molecular modelling studies. Bioorganic & Medicinial Chemistry, vol. 23, Issue 10, pp. 2435-2444 (2015).
International Search Report for Application No. PCT/US08/50374 dated Oct. 28, 2008 (7 pages).
International Search Report for Application No. PCT/US2006/026947 dated Nov. 17, 2006 (4 pages).
Invitation to Pay Additional Fees and Partial International Search Report for International Application No. PCT/US2009/051569 dated Oct. 15, 2009 (4 pages).
International Search Report and Written Opinion for International Application No. PCT/US2017/049473 dated Nov. 30, 2017 (15 pages).
Announcement, “Aerie Pharmaceuticals, Inc. Announces Positive Phase 2a Clinical Results for a Fixed Combination of its Rho Kinase Inhibitor, AR-12286, with Travoprost for the Treatment of Glaucoma” (Nov. 1, 2012) Retrieved from the Internet: URL:http://www.biospace.com.
Announcement, “Aerie Pharmaceuticals Announces Positive Phase 2a Clinical Results for its Novel, Dual Mechanism, AR-13324, for the Treatment of Glaucoma” (Nov. 1, 2012).
Bito et al., Textbook excerpt, The ocular effects of prostaglandin and other eicosanoids. New York, Progress in clinical and biological research (cover, content, abstract, p. 329, 343, 344) (1989).
Colligris et al., Potential role of Rho-associated protein kinase inhibitors for glaucoma treatment. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 6:89-98 (2012).
Fogagnolo et al., Medical treatment of glaucoma: present and future. Expert Opinion on Investigational Drugs, 20 (7):947-959 (2011).
Gennaro, Alfons, R. Remington's Pharmaceutical Sciences, 1985, 17th Edition, pp. 1418-1419.
Hahmann et al., Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity. Cell. Mol. Life Sci., 67:171-177 (2010).
Handbook of Pharmaceutical Salts, Editors: P. Heinrich Stahl and Camille G. Wermuth, Introduction Chapter, pp. 1-7 (2002).
Mizuno et al., Ocular hypotensive mechanism of K-115, a rho-kinase inhibitor, and rho-kinase expression in the eye. ARVO Annual Meeting Abstract, Apr. 2011, Investigative Ophthalmology & Visual Science, vol. 52, 237 (2011).
Paulekuhn et al., Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book database. J. Med. Chem., 50:6665-6672 (2007).
Press Release, Kowa Company Ltd., Kowa Announces the Efficacy and Safety of a Novel Rho Kinase Inhibitor (K-115) in the Treatment of Glaucoma, May 9, 2011. The Association for Research in Vision and Ophthalmology (ARVO) 2011.
Song et al., Fasudil, a Rho-associated protein kinase inhibitor, attenuates retinal ischemia and reperfusion injury in rats. International Journal of Molecular Medicine, 28:193-198 (2011).
Yu et al., Mechanisms, Clinical Profile and Role of Prostaglandin and Prostamide Analogues in Antiglaucomatous Therapy. English Abstract. Published Online Jan. 2013, 230:127-132 (2013).
Amano et al., Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell polarity. Cytoskeleton, 67:545-554 (2010).
Related Publications (1)
Number Date Country
20220331308 A1 Oct 2022 US
Provisional Applications (1)
Number Date Country
62382237 Aug 2016 US
Continuations (2)
Number Date Country
Parent 17841433 Jun 2022 US
Child 17858889 US
Parent 15691607 Aug 2017 US
Child 17841433 US